Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Special Report The 3 Penny Stocks You Swore You'd Never Buy (But You'll Check Anyway)Reported by Chris Markoch. Date Posted: 1/18/2026. 
At a Glance - Vaxart is a clinical-stage biotech developing oral vaccines that could transform global immunization if its platform proves effective.
- Microvision develops cost-effective lidar technology for autonomous vehicles, with upside tied to industry adoption and potential partnerships.
- Datavault AI focuses on monetizing digital data through AI and blockchain tools, offering speculative exposure to the emerging data-as-an-asset theme.
Penny stocks attract speculative investors seeking high-risk, high-reward opportunities. That typically means targeting companies with disruptive technologies, those tied to an emerging trend, or firms with compelling turnaround stories. Many of these companies will never survive or scale, but if even one succeeds, investors can realize outsized returns. For investors who believe strength lies in numbers, MarketBeat offers a tool that lists the 100 Most Popular Penny Stocks. The ranking is based on the number of MarketBeat subscribers following each company. While that's no guarantee of success, it can help investors build conviction in a stock's potential. Some analysts are revisiting historical monetary resets and the role gold has played when governments faced large debt imbalances.
A new free report examines how gold was previously revalued to support national balance sheets, why recent comments from policymakers and investors have renewed interest in this topic, and what individuals may want to understand about protecting long-term savings during periods of monetary change. Download the free report here Definitions vary, and some investors consider a "penny stock" any stock trading for $5 or less. The stocks in this screener use the traditional definition: shares trading below $1. These stocks are highly volatile. Do your own research and understand your risk tolerance before initiating a position. Vaxart: A Potential Game-Changer for Global Immunization Efforts Vaxart Inc. (NASDAQ: VXRT) is a clinical-stage biotechnology company developing oral vaccines for infectious diseases, including influenza, norovirus, and COVID-19. Unlike traditional injectable vaccines, Vaxart's tablet-based platform aims to simplify distribution and improve global accessibility. The bull case for Vaxart centers on its innovative delivery approach. If the company can obtain FDA approval and successfully scale manufacturing and distribution, its oral vaccines could reduce logistical barriers to mass immunization and create significant licensing opportunities. Positive trial results or a commercial collaboration could rapidly shift sentiment and valuation from the stock's current low base. Clinical risk remains the primary challenge. Vaxart has not yet brought a product to market, and vaccine development is costly and unpredictable. Competition from established players with larger R&D budgets also limits visibility. For now, Vaxart is a long-term speculative bet on platform validation rather than near-term profitability. The MarketBeat analyst coverage for Vaxart is sparse, with just a single analyst following the stock—something investors should note. Institutional ownership is about 18%, while short interest is roughly 2%, which may temper some volatility. Microvision: Developing Cost-Effective LiDAR Units For Autonomous Driving Microvision Inc. (NASDAQ: MVIS) develops LiDAR (light detection and ranging) sensors for autonomous vehicles, smart infrastructure, and industrial sensing. Its hardware and software solutions enable precise 3D mapping needed for self-driving systems and advanced driver-assistance systems (ADAS). Microvision focuses on compact, cost-effective LiDAR units that could appeal to automakers seeking scalable sensor solutions. The bullish case rests on two potential catalysts: continued progress toward vehicle automation and strategic partnerships with major automakers. If Microvision can demonstrate a cost or performance advantage, it could secure supply agreements or licensing deals that materially improve revenue visibility. The company's technology could also be applied to robotics and smart-city infrastructure, adding useful optionality to its growth story. That said, Microvision faces stiff competition from LiDAR players such as Luminar (NASDAQ: LAZR), Innoviz (NASDAQ: INVZ), and Ouster (NYSE: OUST). The timeline to widespread commercial adoption of automotive LiDAR has repeatedly slipped, and the path to profitability remains uncertain—factors that have frustrated investors. MVIS is covered by three analysts and carries a consensus price target of $2.50, implying a roughly 169% upside from its Jan. 15 closing price. Institutional ownership is modest (around 30%), while short interest is elevated (about 21%), signaling potential for significant volatility. Datavault AI: Trying to Democratize Data Ownership Datavault AI Inc. (NASDAQ: DVLT) operates at the intersection of artificial intelligence, data monetization, and digital asset management. The company helps organizations convert raw data into tradable, revenue-generating assets through its patented Datavault platform. By combining AI, blockchain, and analytics, Datavault AI aims to democratize data ownership and unlock monetization opportunities that traditional systems may miss. The bullish thesis for Datavault AI rests on its niche focus and potential scalability. As data becomes an increasingly valuable commodity, businesses—and individuals—are seeking secure ways to monetize digital information. Datavault's technology could benefit from broader AI adoption and heightened interest in data sovereignty. Early traction or strategic partnerships could act as catalysts for investor confidence. However, Datavault AI operates in a highly experimental space. Its business model is still evolving, and the path to meaningful revenue growth is unproven. Institutional ownership is under 1%, and short interest exceeds 16% at the time of writing. Investors considering DVLT should treat it as a long-term, speculative position based on the promise of data-as-an-asset innovation rather than near-term earnings. Bottom line: VXRT, MVIS, and DVLT are speculative, early-stage ideas with distinct upside catalysts but substantial risks. Do your own due diligence, consider position sizing carefully, and be prepared for significant volatility if you choose to invest.
| 
